Supplemental material
Leukemia & Lymphoma
Volume 64, 2023 - Issue 2
Articles
Real-world experience of Australian and New Zealand patients with chronic lymphocytic leukemia and mantle cell lymphoma accessing ibrutinib through a Named Patient Program
Stephen P. Mulligana Department of Haematology, Royal North Shore Hospital, Sydney, AustraliaCorrespondence[email protected]
https://orcid.org/0000-0003-1928-2098View further author information
https://orcid.org/0000-0003-1928-2098View further author information, Stephen Opatb Monash Health, Monash University, Melbourne, Australiahttps://orcid.org/0000-0002-0308-6458View further author information
https://orcid.org/0000-0002-0308-6458View further author information, Chan Y. Cheahc Department of Haematology, Sir Charles Gairdner Hospital, Perth, Australia;d Department of Haematology, Pathwest Laboratory Medicine, Perth, Australia;e School of Medicine, University of Western Australia, Perth, Australiahttps://orcid.org/0000-0001-7988-1565View further author information
https://orcid.org/0000-0001-7988-1565View further author information, , , , , , , Robert Weinkovem Te Rerenga Ora Blood & Cancer Centre, Wellington Hospital, Wellington, New Zealand;n Cancer Immunotherapy Programme, Malaghan Institute of Medical Research, Wellington, New Zealandhttps://orcid.org/0000-0003-3645-7988View further author information
https://orcid.org/0000-0003-3645-7988View further author information & show all